A man in a blue shirt signing a document
A man in a blue shirt signing a document

Financial Information

Take a closer look at our Financial Guidance 2023 and the Fundamentals of MorphoSys.


Morphosys Annual Report 2023
Annual Report 2023
Teaser Annual Report 2022
Annual Report 2022


  • Consolidated Financial Statements (IFRS) 2010 |
  • Annual Report 2010 |
  • Financial Statements 2010 of MorphoSys AG (German GAAP - HGB) |
  • Nine Months' Report 2010 |
  • Six Months' Report 2010 |
  • Three Months’ Report 2010 |

Financial Guidance 2024

As a consequence of the sale and transfer of tafasitamab to Incyte on February 5, 2024, MorphoSys' 2024 financial guidance published on January 30, 2024, cannot be maintained and therefore was revoked. For the time being, MorphoSys will no longer make a forecast for revenues from product sales, as no such revenues will be realized.

For 2024, the Group expects R&D expenses of € 170 million to € 185 million. R&D expenses mainly represent our investments in the development of pelabresib and tulmimetostat. Selling, administrative and general expenses are expected to be between € 90 million and € 105 million. Any effects from the implementation of the Novartis takeover offer are not included in this forecast.

The overall forecast is subject to a number of uncertainties, including inflation and foreign currency effects.